PatternsRadar
Sign in

EMCUREEmcure Pharmaceuticals Limited

NSE
Full chart
1,922.40INR-14.70 (-0.76%)Close · 6 Oct 2026
6 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹36,470 CrMarket cap
35.8P/E (TTM)
83.3%Delivery

Filings & corporate actions

9 results filed
CSV
Next results · Q2 FY27
Expected 4 Nov 2026 – 21 Nov 2026
Estimate: filed 35–52 days after quarter end, last 8 times
Dividend
₹3.60 per share · last 4 Sept 2026
2026
  • 4 SeptdividendDividend · ₹3.60 per share+3.9%
  • 6 AugresultsResults · Q1 FY27 · consolidated and standalone-1.1%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026+3.4%NSE
  • 5 MayresultsResults · Q4 FY26 · consolidated and standalone-1.8%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026+2.0%NSE
  • 4 FebresultsResults · Q3 FY26 · consolidated and standalone+1.9%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-0.9%NSE

Reaction to results · all yearsrose on day 0 in 4 of 9 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY276 Aug 2026-1.1%+2.6%-5.3%1.8×
Q4 FY265 May 2026-1.8%-2.0%+3.2%1.6×
Q3 FY264 Feb 2026+1.9%-0.5%-3.5%1.8×
Q2 FY2611 Nov 2025-2.4%0.0%+2.9%1.2×
Q1 FY267 Aug 2025-1.5%+2.3%-4.8%2.3×
Q4 FY2522 May 2025+10.0%+13.9%+12.4%3.1×
Q3 FY256 Feb 2025+2.8%-14.8%-22.3%2.9×
Q2 FY258 Nov 2024-3.2%-9.3%-5.0%7.5×
Q1 FY2513 Aug 2024+0.5%+9.9%+16.6%1.5×
Average+0.6%+0.2%-0.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+22.8%
Profit YoY+36.2%
Interest cost YoY+3.3%
Revenue QoQ+4.5%
Profit QoQ+20.0%
CAGR2Y3Y4Y5Y6Y7Y
Revenue——————
Profit——————

Key data

CSV
Open1,937.10
Day range1,890.00 – 1,954.90
52-week range1,260.00 – 2,100.70
From 52w high-8.5%
RSI (14)47.5
ATR (14)57.37
Volume3.80L
Avg volume (20D)2.16L
Rel volume1.76×
Volatility (1Y)32.5%
Turnover₹73.0Cr
SMA 50 / 2001,928.90 / 1,688.02

Delivery percentage

Latest · 6 Oct 202683.3%
20-day avg52.0%
1-year avg50.9%
Percentile (own history)98th
Range12.6–93.4%
Sessions556

Over the last 20 sessions EMCURE settled 52.0% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 50.9%. The latest session ranks higher than 98% of the 556 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-0.76%-0.28%+3.65%+4.28%+24.22%+49.70%

Valuation

CSV
Market cap₹36,470 Cr
P/E (TTM)35.8
EPS (TTM)53.71
Shares outstanding18.97Cr
Listed10 Jul 2024

Ownership

CSV
Promoter77.83%
Promoter Δ QoQ-0.04 pp
Public22.17%
FII4.88%
DII8.46%
Pledged0.04%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)2,269.82,363.52,469.72,580.4
YoY chg+13.4%+20.4%+16.7%+22.8%
Net profit (₹ Cr)251.4231.4243.7292.5
YoY chg+24.7%+48.2%+23.6%+36.2%
Net margin11.1%9.8%9.9%11.3%
EPS12.8512.1612.8415.50

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 77.83% · public 22.17%
8 Jul 2024: promoter 78.08%30 Sept 2024: promoter 78.08%31 Dec 2024: promoter 77.94%31 Mar 2025: promoter 77.92%30 Jun 2025: promoter 77.91%30 Sept 2025: promoter 77.88%31 Dec 2025: promoter 77.87%31 Mar 2026: promoter 77.87%30 Jun 2026: promoter 77.83%
2024-072026-06
  • Promoter
  • Public and others
Promoter
77.83%
Public
22.17%
Promoter change
-0.04 pp
Filed
21 Jul 2026
FII
4.88%
DII
8.46%
Promoter pledged
0.04%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue from operations1,815.12,002.01,962.62,116.22,100.52,269.82,363.52,469.72,580.4
Other income23.435.73.94.53.73.11.94.02.1
Total income1,838.62,037.61,966.52,120.72,104.22,272.92,365.32,473.72,582.5
Total expenses1,631.21,764.21,736.61,849.71,810.01,931.52,013.42,142.82,189.0
└ Finance costs58.846.231.839.026.832.538.046.431.5
└ Depreciation93.696.996.896.899.5104.6104.7106.3109.5
Profit before tax207.4273.4229.9260.6290.8341.4313.8341.2393.5
Tax expense54.871.973.863.476.090.082.497.4101.0
Net profit152.6201.5156.1197.2214.8251.4231.4243.7292.5
EPS7.9510.338.129.9710.9212.8512.1612.8415.50
Net margin8.41%10.07%7.95%9.32%10.23%11.07%9.79%9.87%11.33%
PBT margin11.43%13.66%11.71%12.31%13.84%15.04%13.28%13.81%15.25%
Tax rate26.43%26.28%32.11%24.32%26.13%26.37%26.27%28.56%25.67%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 6 Aug 2026.

EMCURE at a glance

  • EMCURE closed at ₹1,922.4 on 6 Oct 2026, -0.76% on the day, +49.7% over one year, 8.5% below its 52-week high of ₹2,100.7.
  • Delivery was 83.3% of traded quantity on 6 Oct 2026, the 98th percentile of its own 556 sessions with a reading (20-session average 52.0%, 1-year average 50.9%).
  • Market capitalisation is ₹36,470 crore at a trailing P/E of 35.8 (trailing EPS ₹53.71).
  • Q1 FY27 results (consolidated, filed 6 Aug 2026): revenue ₹2,580 crore (+22.8% year on year), net profit ₹292 crore (+36.2%); the price moved -1.1% on the first session after.
  • Promoters held 77.83% at 30 Jun 2026, down 0.04 percentage points on the previous filing, with 0.04% of promoter shares pledged.
  • Q2 FY27 results are expected between 4 Nov 2026 and 21 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE168P01015
SeriesEQ
Listed10 Jul 2024
History from10 Jul 2024
Sessions556
Turnover rank#525

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE